2024
TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy
Bardia A, Pusztai L, Albain K, Ciruelos E, Im S, Hershman D, Kalinsky K, Isaacs C, Loirat D, Testa L, Tokunaga E, Wu J, Dry H, Barlow W, Kozarski R, Maxwell M, Harbeck N, Sharma P. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241248336. PMID: 38686016, PMCID: PMC11057345, DOI: 10.1177/17588359241248336.Peer-Reviewed Original ResearchInvasive disease-free survivalResidual invasive diseasePathological complete responseTriple-negative breast cancerDisease-free survivalNeoadjuvant therapyInvasive diseaseSurgical resectionBreast cancerHigh risk of disease recurrenceTopoisomerase I inhibitor payloadRisk of disease recurrenceStandard-of-care therapyAdjuvant treatment approachesPhase III studyTreatment of patientsWritten informed consentAntibody-drug conjugatesAged 18-yearsComplete responseNeoadjuvant treatmentInstitutional review boardOverall survivalDisease recurrenceIII studies
2010
Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer
Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to Predict Subsequent Brain Metastasis in Patients With Metastatic Breast Cancer. Journal Of Clinical Oncology 2010, 28: 2032-2037. PMID: 20308667, DOI: 10.1200/jco.2009.24.6314.Peer-Reviewed Original ResearchConceptsSubsequent brain metastasesBrain metastasesMetastatic breast cancerBreast cancerPatient populationMethods Electronic medical recordsStage IV breast cancerHuman epidermal growth factor receptor 2Shorter disease-free survivalEpidermal growth factor receptor 2Multivariate logistic regression analysisDisease-free survivalGrowth factor receptor 2Logistic regression analysisDesign of trialsFactor receptor 2Cross Cancer InstituteElectronic medical recordsInstitutional review boardMetastatic diseaseMetastatic sitesPrevention trialsPrognostic featuresClinical nomogramMedical records
2007
Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients
Sun A, Yu T, Wang L, Lu J, Gonzales G, Pusztai L, Singletary S, Ross M, Wei Q, Buchholz T. Nijmegen breakage syndrome 1 (NBS1) gene polymorphism and chemotherapy-induced neutropenic fever in breast cancer patients. Journal Of Clinical Oncology 2007, 25: 574-574. DOI: 10.1200/jco.2007.25.18_suppl.574.Peer-Reviewed Original ResearchBreast cancer patientsAbsolute neutrophil countChemotherapy-induced neutropenic feverNeutropenic feverCancer patientsC polymorphismChemotherapy-induced bone marrow toxicityGene polymorphismsMultivariable logistical regression analysisMultivariable logistic regression modelGrowth factor supportPolymerase chain reaction-restriction fragment length polymorphism methodBone marrow toxicityTwo-sided ChiFragment length polymorphism methodGrowth factor useLogistical regression analysisLength polymorphism methodLogistic regression modelsInstitutional review boardNBS1 geneSystemic chemotherapyNeutrophil countChemotherapy administrationFactor support